Oncogenic roles of ATAD2 by regulating cell cycle progression in T-ALL. (A) The efficiency of ATAD2 KD by shRNA (shATAD2) vs scramble shRNA control (shNC) in CEM (left) and MOLT4 (right) cells by western blot. (B) Effect of ATAD2 KD vs shNC on cell proliferation in CEM (left) and MOLT4 (right) cells. (C-D) Effect of ATAD2 KD vs shNC on cell cycle progression in CEM cells (C, representative images; D, bar graph). (E-F) Effect of ATAD2 silence by shRNA vs shNC on Kaplan-Meier survival curves (E), and percentage of human CD45⁺CD7⁺ cells (F) in the spleen and BM of the xenograft mouse model. The mice were IV injected with the CEM-shNC or CEM-shATAD2 cells, respectively, for 28 days, and the single cells were prepared and analyzed. (G) Comparison of ATAD2 mRNA level in our T-ALL cohorts vs normal BM controls. The mRNA levels were determined by qPCR assay. (H) Association of ATAD2 expression with relapse in our cohort. (I) Comparison of ATAD2 mRNA levels in 5 pairs of T-ALL newly diagnosed samples vs relapsed ones. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001.